Eli Lilly posts downbeat 2016 outlook

6 January 2016
lilly-logo-big

US drug major Eli Lilly (NYSE: LLY) has announced full year revenues for 2016 guidance, which misses analyst estimates partly from the impact of foreign-exchange headwinds.

The company said it expects sales in 2016 in the range of $20.2 billion and $20.7 billion, below analyst estimates of $21.4 billion, partly hurt by the strong dollar. Earnings per share are forecast between $3.45 and $3.55, against analyst estimates of $3.65 per share.

Eli Lilly maintained its full-year 2015 earnings per share outlook at $3.40 to $3.45.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical